Inicia sesión Registrate Mi Biblioteca idioma

Idioma

biblioteca idioma abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará la selección de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por International Parkinson & Movement Disorder Society.

Corea y enfermedad de Huntington

263 ARTíCULOS , VIENDO DEL 241 AL 255

PUBMED

Quality Control in Huntington's Disease: a Therapeutic Target.

Rai SN, Singh BK, Rathore AS, Zahra W, Keswani C, Birla H, Singh SS, Dilnashin H, Singh SP.

Neurotox Res. 2019 Oct;36(3):612-626. doi: 10.1007/s12640-019-00087-x. Epub 2019 Jul 11. Review.

0

0

0

PUBMED

Autoregressive modeling to assess stride time pattern stability in individuals with Huntington's disease.

Alzakerin HM, Halkiadakis Y, Morgan KD.

BMC Neurol. 2019 Dec 9;19(1):316. doi: 10.1186/s12883-019-1545-6.

0

0

0

PUBMED

Longitudinal study revealing motor, cognitive and behavioral decline in a transgenic minipig model of Huntington's disease.

Baxa M, Levinska B, Skrivankova M, Pokorny M, Juhasova J, Klima J, Klempir J, Motlı K J, Juhas S, Ellederova Z.

Dis Model Mech. 2019 Dec 12;13(2). pii: dmm041293. doi: 10.1242/dmm.041293.

0

0

0

PUBMED

A Combinatorial Cell and Drug Delivery Strategy for Huntington's Disease Using Pharmacologically Active Microcarriers and RNAi Neuronally-Committed Mesenchymal Stromal Cells.

André EM, Delcroix GJ, Kandalam S, Sindji L, Montero-Menei CN.

Pharmaceutics. 2019 Oct 12;11(10). pii: E526. doi: 10.3390/pharmaceutics11100526.

0

0

0

PUBMED

Duty of care versus patient confidentiality: High Court hears test case on Huntington's disease.

Dyer C.

BMJ. 2019 Nov 19;367:l6600. doi: 10.1136/bmj.l6600. No abstract available.

0

0

0

PUBMED

Lercanidipine boosts the efficacy of mesenchymal stem cell therapy in 3-NP-induced Huntington's disease model rats via modulation of the calcium/calcineurin/NFATc4 and Wnt/β-catenin signalling pathways.

Elbaz EM, Helmy HS, El-Sahar AE, Saad MA, Sayed RH.

Neurochem Int. 2019 Dec;131:104548. doi: 10.1016/j.neuint.2019.104548. Epub 2019 Sep 17.

0

0

0

PUBMED

Improving follow up after predictive testing in Huntington's disease: evaluating a genetic counselling narrative group session.

Stopford C, Ferrer-Duch M, Moldovan R, MacLeod R.

J Community Genet. 2019 Apr 18. doi: 10.1007/s12687-019-00416-9. [Epub ahead of print]

0

0

0

PUBMED

Novel proteomic changes in brain mitochondria provide insights into mitochondrial dysfunction in mouse models of Huntington's disease.

Agrawal S, Fox JH.

Mitochondrion. 2019 Mar 20. pii: S1567-7249(18)30075-8. doi: 10.1016/j.mito.2019.03.004. [Epub ahead of print]

0

0

0

PUBMED

Health state utility values (QALY weights) for Huntington's disease: an analysis of data from the European Huntington's Disease Network (EHDN).

Hawton A, Green C, Goodwin E, Harrower T.

Eur J Health Econ. 2019 Dec;20(9):1335-1347. doi: 10.1007/s10198-019-01092-9. Epub 2019 Aug 13.

0

0

0

PUBMED

Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease.

Wright GEB, Collins JA, Kay C, McDonald C, Dolzhenko E, Xia Q, Bečanović K, Drögemöller BI, Semaka A, Nguyen CM, Trost B, Richards F, Bijlsma EK, Squitieri F, Ross CJD, Scherer SW, Eberle MA, Yuen RKC

Am J Hum Genet. 2019 May 8. pii: S0002-9297(19)30153-3. doi: 10.1016/j.ajhg.2019.04.007. [Epub ahead of print]

0

0

0

PUBMED

Gintonin, a ginseng-derived ingredient, as a novel therapeutic strategy for Huntington's disease: Activation of the Nrf2 pathway through lysophosphatidic acid receptors.

Jang M, Choi JH, Chang Y, Lee SJ, Nah SY, Cho IH.

Brain Behav Immun. 2019 Mar 7. pii: S0889-1591(18)30392-1. doi: 10.1016/j.bbi.2019.03.001. [Epub ahead of print]

0

0

0

PUBMED

Alterations in Hippocampal Inhibitory Synaptic Transmission in the R6/2 Mouse Model of Huntington's Disease.

Dargaei Z, Liang X, Serranilla M, Santos J, Woodin MA.

Neuroscience. 2019 Apr 15;404:130-140. doi: 10.1016/j.neuroscience.2019.02.007. Epub 2019 Feb 22.

0

0

0

PUBMED

Conformational studies of pathogenic expanded polyglutamine protein deposits from Huntington's disease.

Matlahov I, van der Wel PC.

Exp Biol Med (Maywood). 2019 Dec;244(17):1584-1595. doi: 10.1177/1535370219856620. Epub 2019 Jun 15. No abstract available.

0

0

0

PUBMED

Selection of Reference Regions to Model Neurodegeneration in Huntington Disease by 18F-FDG PET/CT Using Imaging and Clinical Parameters.

López Mora DA, Sampedro F, Camacho V, Fernández A, Fuentes F, Duch J, Pérez-Perez J, Martínez-Horta S, Marín-Lahoz J, Domènech A, Flotats A, Estorch M, Kulisevsky J, Carrió I.

Clin Nucl Med. 2019 Jan;44(1):e1-e5. doi: 10.1097/RLU.0000000000002329.

0

0

0

PUBMED

Clinical manifestations of homozygote allele carriers in Huntington disease.

Cubo E, Martinez-Horta SI, Santalo FS, Descalls AM, Calvo S, Gil-Polo C, Muñoz I, Llano K, Mariscal N, Diaz D, Gutierrez A, Aguado L, Ramos-Arroyo MA; European HD Network..

Neurology. 2019 Apr 30;92(18):e2101-e2108. doi: 10.1212/WNL.0000000000007147. Epub 2019 Mar 13.

0

0

0

Comentarios

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo HONcode Logo WIS

En colaboración con:

Zambon Neuroacademy